Joseph Apostol, MD
Cardiovascular Disease · Billings, MTNPI 1497781512
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,154 of the $11,600 with a category attached, or 70.3%. 29 manufacturers reported payments, led by Abbott at 29.2% of the total. Reporting peaked in 2019 at $4,517 and has fallen 80.2% since, to $896 in 2025.
Across 368 payments — averaging $31.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Boston Scientific$3K
- E.r. Squibb & Sons, L.L.C.$1K
- Medtronic$1K
- Johnson & Johnson$768
- Novartis$512
- plus $1K from 23 others
What the payments were for
- Travel & lodging$3,36329%
- Food & beverage$8,15470%
- Education$841%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 31 | $3,393 |
| Boston Scientific | 65 | $2,625 |
| E.r. Squibb & Sons, L.L.C. | 47 | $1,499 |
| Medtronic(2 entities) | 24 | $1,327 |
| Johnson & Johnson | 78 | $768 |
| Novartis | 31 | $512 |
| AstraZeneca | 24 | $374 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 18 | $222 |
| Abiomed | 16 | $216 |
| Edwards Lifesciences | 4 | $158 |
| Merck | 8 | $141 |
| Pfizer | 4 | $58 |
| Terumo Medical Corporation | 2 | $33 |
| Shockwave Medical, Inc | 1 | $31 |
| Bayer | 1 | $22 |
| Tactile Systems Technology Inc | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $20 |
| Asahi Intecc USA, Inc. | 1 | $19 |
| Chiesi USA, Inc. | 1 | $19 |
| Impulse Dynamics (USA) Inc. | 1 | $16 |
| Amgen | 1 | $15 |
| Acist Medical Systems, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Siemens Medical Solutions USA, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $12 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| EKOS Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xience V coronary stent system$2,098
- Watchman$1,294
- CAMZYOS$729
- MitraClip$149
- WATCHMAN Access System$147
- Micra$103
- Xience Sierra Coronary Stent System$102
How this compares
$11,600 in reported general payments places this provider in the 85th percentile of 49 cardiovascular disease providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 385 | $347,272 |
| CamzyosMavacamten | 26 | $222,450 |
| XareltoRivaroxaban | 139 | $145,941 |
| EntrestoSacubitril/Valsartan | 125 | $120,397 |
| Repatha SureclickEvolocumab | 86 | $54,641 |
| BrilintaTicagrelor | 42 | $30,249 |
| JardianceEmpagliflozin | 19 | $24,333 |
| FarxigaDapagliflozin Propanediol | 31 | $17,874 |
| Praluent PenAlirocumab | 34 | $16,629 |
| Repatha SyringeEvolocumab | 12 | $6,603 |
| CorlanorIvabradine Hcl | 11 | $6,226 |
| DapagliflozinDapagliflozin Propanediol | 11 | $4,608 |
| Metoprolol Succinate | 398 | $4,194 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 209 | $2,565 |
| ClopidogrelClopidogrel Bisulfate | 269 | $2,559 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $58 | $347,272385 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $1,499 | $222,45026 claims |
| Johnson & JohnsonXarelto | $768 | $145,941139 claims |
| NovartisEntresto | $512 | $120,397125 claims |
| AstraZenecaBrilinta, Farxiga | $374 | $48,12373 claims |
| Boehringer IngelheimJardiance | $12 | $24,33319 claims |
| AmgenCorlanor | $15 | $6,22611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 49 cardiovascular disease providers in Montana.
Other cardiovascular disease in Billings
- Benjamin PlankBillings$46K
- Douglas WaldoBillings$3K
- Jeffrey SmithBillings$2K
- Christopher AnzaloneBillings$2K
- Arthur RabinowitzBillings$1K
- Emily HansonBillings$1K
- Joseph CondonBillings$950
- Barbara DudczakBillings$300
- Clara KwanBillings$276
- Chris LinBillings$125
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.